Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Molecular & Cellular Oncology|November 25, 2020
CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancerJiachen Xuan, Richard B Pearson, Elaine SanijGenes|August 27, 2021
Harnessing the Nucleolar DNA Damage Response in Cancer TherapyJiachen Xuan, Kezia Gitareja, Natalie Brajanovski, et al.Signal Transduction and Targeted Therapy|August 31, 2021
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapyJian Kang, Natalie Brajanovski, Keefe T Chan, et al.British Journal of Cancer|November 11, 2020
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancerShunfei Yan, Jiachen Xuan, Natalie Brajanovski, et al.The EMBO Journal|July 23, 2026
RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stabilityRuofei Liu, Jiachen Xuan, Carmelo Cerra, et al.Nature Cell Biology|November 9, 2021
The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 functionKatarzyna Koltowska, Kazuhide S Okuda, Marleen Gloger, et al.Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.Pageof 1